一种与骨髓性三症21相关的基因变异对阿尔茨海默病有保护作用
Mengmeng Jin1, Ziyuan Ma1, Rui Dang1
1Department of Cell Biology and Neuroscience, Rutgers University-New Brunswick, Piscataway, NJ, USA.
Nature neuroscience
|November 25, 2025
概括
微质中的某些与唐氏综合征相关的突变可能会增强对阿尔茨海默氏症病理学的抵抗力. 在小鼠中,表达这种突变的工程微细胞保护了神经元并保留了认知功能.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 免疫学 免疫学 免疫学
背景情况:
- 阿尔茨海默病 (AD) 涉及渐进的认知衰退,但一些人表现出性,尽管AD病理.
- 由于遗传因素,唐氏综合征 (DS) 显著增加了AD风险.
- 造血突变在DS中更为常见,这表明它可能在微质弹性中发挥作用.
研究的目的:
- 为了调查与唐氏综合征相关的特定髓状突变 (CSF2RB A455D) 是否赋予微质弹性.
- 评估这种突变对人类微质细胞在毛病病症小鼠模型中的功能影响.
主要方法:
- 引入了CSF2RB A455D突变到人类多能干细胞衍生微质中,来自DS和健康的捐赠者.
- 研究了这些工程微质细胞在暴露于病理的嵌合体小鼠 (4-10个月大) 中的功能.
- 评估了微质反应,包括炎症,细胞化,衰老和神经元保护.
主要成果:
- 该CSF2RB A455D突变抑制了I型干扰素信号传递,减少了对tau病理反应的炎症.
- 突变的微质细胞表现出增强的细胞分裂和改善的微质衰老.
- 表达CSF2RB A455D的微质形成了一个保护性亚群,保留了神经元功能,并取代了患病的野生类型微质.
结论:
- CSF2RB A455D突变增强了微质细胞对诱导病理的抵抗力.
- 工程人类微质细胞可以作为一种治疗策略,以提高阿尔茨海默病的恢复力.
- 这项研究提供了微质质替代疗法的概念证明.
更多相关视频
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
12.2K
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
34.5K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
